- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04277845
Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma (KMM1910)
Randomized Phase II Study of Bortezomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Elderly Patients With Newly Diagnosed Multiple Myeloma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Group 1: 1 cycle will be repeated every 4 weeks
Bortezomib 1.3mg/m2 SC D1, 8, 15
- Dose adjustment for more than 85 : 1.0mg/m2 SC D1, 8, 15
Lenalidomide 25mg/d D1-21
- Dose adjustment for more than 75 : 15mg/d D1-21
Dexamethasone 40mg D1, 8, 15, 22
- Dose adjustment for more than 75 years old: 20mg
- If it is difficult to maintain bortezomib due to unacceptable toxicity, it can early discontinue from Group 1.
<for patients with old age or frail>
- Bortezomib 1.0mg/m2 SC D1, 8, 15 : Dose adjustment for more than 85 : 1.0mg/m2 SC D1,8,15
- Lenalidomide 15mg/d D1-21
- Dexamethasone 20mg D1, 8, 15, 22
Group 2: 1 cycle will be repeated every 4 weeks
- Lenalidomide 25mg/d D1-21 - Dose adjustment for more than 75: 15mg
- Dexamethasone 40mg D1, 8, 15, 22 - Dose adjustment for more than 75: 20mg <for patients with old age or frail>
1) Lenalidomide 15mg/d D1-21 2) Dexamethasone 20mg D1, 8, 15, 22
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
[Inclusion criteria]
- Newly diagnosed with multiple myeloma
- Older than 70 years
- Ineligible for autologous stem cell transplantation
- No history of prior treatment for multiple myeloma
At least one of the following measuarble disease
- Serum M-protein ≥ 0.5 g/dL, or urine M-protein ≥ 200mg/24 hour, or
- In patients without detectable serum or urine M-protein, serum free light chain (SFLC) > 100 mg/L (involved light chain) and an abnormal serum kappa/lambda ratio.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
- Adequate hepatic functionwith bilirubin < 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULN.
- Left ventricular ejection fraction (LVEF) ≥ 40%.
*Absolute Neutrophil Count (ANC) ≥ 1000/mm³: Screening ANC should be independent of growth factor support for ≥ 1 week;
- Hemoglobin ≥ 8.0 g/dL (Use of erythropoietic stimulating factors and red blood cell transfusions is allowed);
- Platelet count ≥ 50,000/mm³ (≥ 30,000/mm³ -if myeloma involvement in the bone marrow is >50%): Patients should not have received platelet transfusions
- for at least 1 week prior to obtaining the screening platelet count.
Calculated or measured creatinine clearance (CrCl) of ≥ 15 mL/min
- Calculation should be based on standard formula such as the Cockcroft and Gault: [(140 - Age) x Mass (kg) / (72 x Creatinine mg/dL)]; multiply result by 0.85 if female.
- Written informed consent in accordance with institutional guidelines.
Female patients of child-bearing potential (FCBP) must have two negative pregnancy tests (sensitivity of at least 25 mIU/mL) prior to starting lenalidomide. The first pregnancy test must be performed within 10 to 14 days prior to the start of lenalidomide and the second pregnancy test must be performed within 24 hours prior to the start of lenalidomide.
Effective method of contraception should be used during and for 28 days following last dose of drug
- FCBP is defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
- Male patients must use an effective barrier method of contraception during study and for 28 days following the last dose if sexually active with a FCBP.
[Exclusion criteria]
- Relapsed or refractory multiple myeloma
- Multiple Myeloma of IgM subtype.
- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
- Plasma cell leukemia or circulating plasma cells ≥ 2 × 10^9/L.
- Waldenstrom's Macroglobulinemia.
- Patients with known amyloidosis.
- Patients got approved chemotherapy or investigational anticancer therapeutics within 21 days prior to the 1st day of 1st cycle.
- Focal radiation therapy within 7 days prior to the 1st day of 1st cycle.
- Immunotherapy within 21 days prior to the 1st day of 1st cycle.
- Major surgery (excluding kyphoplasty) within 28 days prior to 1st day of 1st cycle.
- Active congestive heart failure (New York Heart Association [NYHA] Class III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within four months prior to 1st day of 1st cycle.
- Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at hepatitis B) or antifungal agents within 14 days prior to 1st day of 1st cycle.
- Known human immunodeficiency (HIV) seropositive, hepatitis C infection, and/or hepatitis B (But, allow the patient who is DNA(-) or responding to antiviral therapy even if patient is HBsAg(+) or anti-HBc(+)).
- Patients with known cirrhosis.
- Female patients who are pregnant or lactating.
- Patients with contraindication to dexamethasone.
- Hypersensitivity to antiviral drugs, Contraindication to any of the required concomitant drugs or supportive treatments due to preexisting pulmonary or cardiac impairment.
- Patients with end-stage renal disease requiring hemodialysis or peritoneal dialysis
Patients with a history of malignant tumors other than the target disease, except for the following cases:
- If the tumor has not been treated for at least 5 years or is in a disease-
- At least one year has elapsed since complete resection of basal cell cancer/flat cell cancer or successful treatment of cervical intraepithelial cancer
- Patients with genetic problems such as galactose intolerance, Laplactase deficiency or glucose-galactose malabsorption
- Patients with acute diffuse invasive lung disease and heart disease
- Patients with history of hypersensitivity to Lenalidomide and bortezomib
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Group 1: 1 cycle will be repeated every 4 weeks Bortezomib 1.3mg/m2 SC D1, 8, 15 - Dose adjustment for more than 85 : 1.0mg/m2 SC D1, 8, 15 Lenalidomide 25mg/d D1-21 - Dose adjustment for more than 75 : 15mg/d D1-21 Dexamethasone 40mg D1, 8, 15, 22 - Dose adjustment for more than 75 years old: 20mg If it is difficult to maintain bortezomib due to unacceptable toxicity, it can early discontinue from Group 1. <for patients with old age or frail> Bortezomib 1.0mg/m2 SC D1, 8, 15 : Dose adjustment for more than 85 : 1.0mg/m2 SC D1,8,15 Lenalidomide 15mg/d D1-21 Dexamethasone 20mg D1, 8, 15, 22 |
Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
Other Names:
|
Active Comparator: Group 2
Group 2: 1 cycle will be repeated every 4 weeks Lenalidomide 25mg/d D1-21
<for patients with old age or frail>
|
Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-Year Progression-free survival (PFS)
Time Frame: 3-years after randomization
|
The time from randomization into the date of first observation of documented disease progression or death.
|
3-years after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of response
Time Frame: accessed every each cycle (each cycle is 28days)
|
Response will be determined by the International Myeloma Working Group Response Criteria every cycle
|
accessed every each cycle (each cycle is 28days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Minimal residual disease (MRD)
Time Frame: at the time when patient get CR or VGPR after 1year administration
|
Confirmation of MRD negativity
|
at the time when patient get CR or VGPR after 1year administration
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Lenalidomide
- Bortezomib
Other Study ID Numbers
- SMC 2019-08-025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Bortezomib, Lenalidomide, Dexamethasone
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
European Myeloma NetworkJanssen Research & Development, LLCActive, not recruitingMultiple MyelomaNorway, Denmark, Netherlands, Czechia, Australia, Turkey, Spain, Belgium, Switzerland, France, Greece, Italy, Poland
-
University of Alabama at BirminghamRecruitingMultiple MyelomaUnited States
-
University Hospital, ToulouseDana-Farber Cancer Institute; Celgene Corporation; Janssen-Cilag Ltd.Completed
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...CompletedMultiple MyelomaUnited States
-
Kosin University Gospel HospitalRecruitingWaldenström's MacroglobulinemiaKorea, Republic of
-
Institute of Hematology & Blood Diseases Hospital...Recruiting
-
Ida Bruun KristensenOdense Patient Data Explorative Network; Karyopharm Therapeutics IncActive, not recruitingMultiple MyelomaDenmark, Norway, Estonia
-
H. Lee Moffitt Cancer Center and Research InstituteJanssen Scientific Affairs, LLCActive, not recruitingMultiple MyelomaUnited States